

Resource Summary Report

Generated by T1D on Aug 1, 2026

NIH NCI list of FDA approved cancer drugs

RRID:SCR_021841

Type: Tool

Proper Citation

NIH NCI list of FDA approved cancer drugs (RRID:SCR_021841)

Resource Information

URL: <https://www.cancer.gov/about-cancer/treatment/drugs>

Proper Citation: NIH NCI list of FDA approved cancer drugs (RRID:SCR_021841)

Description: Portal to find consumer friendly information about drugs for cancer and conditions related to cancer. The list is in alphabetical order by generic name and brand name.

Resource Type: topical portal, data or information resource, disease-related portal, portal

Keywords: drugs for cancer, conditions related to cancer, alphabetical order, generic name, brand name

Related Condition: cancer

Availability: Free, Available for download, Freely available

Resource Name: NIH NCI list of FDA approved cancer drugs

Resource ID: SCR_021841

Record Creation Time: 20220129T080357+0000

Record Last Update: 20260801T042843+0000

Ratings and Alerts

No rating or validation information has been found for NIH NCI list of FDA approved cancer drugs.

No alerts have been found for NIH NCI list of FDA approved cancer drugs.

Data and Source Information

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Álvarez-Gómez C, et al. (2025) Design, synthesis, and in vitro evaluation of a carbamazepine derivative with antitumor potential in a model of Acute Lymphoblastic Leukemia. PloS one, 20(4), e0319415.

Yu PC, et al. (2025) Quantitative Proteomics Unveils the Synergistic Effects of Combination Drugs on Cytoskeleton Composition and Autophagy-Mediated Cell Death in Neuroblastoma. Journal of proteome research, 24(7), 3578.

Carli F, et al. (2025) Learning and actioning general principles of cancer cell drug sensitivity. Nature communications, 16(1), 1654.

Hu C, et al. (2024) Optimizing drug combination and mechanism analysis based on risk pathway crosstalk in pan cancer. Scientific data, 11(1), 74.

Flobak Å, et al. (2023) Fine tuning a logical model of cancer cells to predict drug synergies: combining manual curation and automated parameterization. Frontiers in systems biology, 3, 1252961.

Peterson JS, et al. (2023) Growth in eligibility criteria content and failure to accrue among National Cancer Institute (NCI)-affiliated clinical trials. Cancer medicine, 12(4), 4715.

Hartung M, et al. (2022) Cancer driver drug interaction explorer. Nucleic acids research, 50(W1), W138.

Wen H, et al. (2022) Novel pyroptosis-associated genes signature for predicting the prognosis of sarcoma and validation. Bioscience reports, 42(12).

Smith JC, et al. (2022) Genome-wide identification and analysis of prognostic features in human cancers. Cell reports, 38(13), 110569.

Lane S, et al. (2022) Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination. BMJ open, 12(7), e060425.